�物�良�应该由�报告?
  我国《���良�应监测管�办法》(试行)(以下简称《办法》)规定��生产���业和医疗预防��机构按规定报告所�现的���良�应。
  《办法》明确规定了报告的å�•ä½�,但未明确报告人。由于ADR报告的质é‡�和报告人的è�¯ç‰©çŸ¥è¯†å’Œä¸´åºŠç»�éªŒæœ‰å…³ï¼Œå› æ¤ï¼ŒæŠ¥å‘Šäººé€šå¸¸ä¸ºåŒ»å¸ˆã€�è�¯å¸ˆï¼Œä»¥å�ŠæŠ¤å¸ˆç‰å�«ç”ŸæŠ€æœ¯äººå‘˜ã€‚至于患者是å�¦å�¯ä»¥æŠ¥å‘ŠADR,å�„国规定ä¸�尽相å�Œã€‚
  按《办法》第二å��æ�¡è§„定,个人å�‘现è�¯å“�引起的ADRå�¯ä»¥æŠ¥å‘Šã€‚但英国ADR监测机构考,试大网站收集ä¸�直接收患者的ADR报告,而建议患者通过医师ã€�è�¯å¸ˆå¡«å†™é»„å�¡ä¸ŠæŠ¥ï¼Œå¹¶å¯¹æ¤ä½œå‡ºè¯´æ˜Žå¦‚下:
  we do not accept reports directly from patients , as we consider that medical interpretation of the suspected reaction is vital. We advise patients who suspect they have had an adverse reaction to their medicine to discuss this with their doctor or pharmacist. The doctor or pharmacist may then report this via the yellow card scheme, if they consider it to be appropriate.

